Dydrogesterone withdrawn
for commercial reasons
United Kingdom — Dydrogesterone
(Duphaston ®) is to be withdrawn from
the market from March 2008 for commercial
reasons. Dydrogesterone was licensed
for use in several indications,
including threatened or recurrent miscarriage,
dysfunctional uterine bleeding, and
hormone replacement therapy.
A Public Assessment Report has reviewed
evidence for the efficacy of
progesterone and dydrogesterone in the
maintenance of pregnancy in women with
threatened miscarriage or recurrent
miscarriage.
For several decades, progesterone and
progestogens (such as dydrogesterone)
have been used to maintain early pregnancy.
However, this practice seems to
have been based on theoretical considerations
rather than robust evidence of
efficacy. Although the methodological and
ethical difficulties associated with conducting
efficacy trials in these indications
need to be considered, the quality of
much of the evidence is generally poor
relative to today’s standards.
Reference: Medicines and Healthcare
products Regulatory Agency (MHRA) information
release.
We have carefully reviewed our files for records concerning the withdrawal of GYNOREST (dydrogesterone) oral tablets, 5 mg and 10 mg, from sale. We have also independently evaluated relevant literature and data for possible post-marketing adverse events. We have found no information that would indicate that this drug product was withdrawn from sale for reasons of safety or effectiveness.
What I read into that is "withdrawn for commercial reasons".
Dydrogesterone withdrawn for commercial reasons United Kingdom — Dydrogesterone (Duphaston ®) is to be withdrawn from the market from March 2008 for commercial reasons. Dydrogesterone was licensed for use in several indications, including threatened or recurrent miscarriage, dysfunctional uterine bleeding, and hormone replacement therapy. A Public Assessment Report has reviewed evidence for the efficacy of progesterone and dydrogesterone in the maintenance of pregnancy in women with threatened miscarriage or recurrent miscarriage. For several decades, progesterone and progestogens (such as dydrogesterone) have been used to maintain early pregnancy. However, this practice seems to have been based on theoretical considerations rather than robust evidence of efficacy. Although the methodological and ethical difficulties associated with conducting efficacy trials in these indications need to be considered, the quality of much of the evidence is generally poor relative to today’s standards.
Reference: Medicines and Healthcare products Regulatory Agency (MHRA) information release.
We have carefully reviewed our files for records concerning the withdrawal of GYNOREST (dydrogesterone) oral tablets, 5 mg and 10 mg, from sale. We have also independently evaluated relevant literature and data for possible post-marketing adverse events. We have found no information that would indicate that this drug product was withdrawn from sale for reasons of safety or effectiveness.
What I read into that is "withdrawn for commercial reasons".
Not sure about the US case, but for UK I found
The verbiage provided by the FDA is a bit more obscure
What I read into that is "withdrawn for commercial reasons".
Not sure about the US case, but for UK I found
The verbiage provided by the FDA is a bit more obscure
What I read into that is "withdrawn for commercial reasons".
More
VOTE
VOTE